The syndrome of partial mole.
One hundred and six patients with complete mole and 35 patients with partial mole were analysed. The clinical behaviour of complete mole was more florid. The clinical diagnosis of partial mole was more difficult. 20.7% of the complete mole patients and 11.4% of the partial mole patients required chemotherapy because of persistent or metastatic trophoblastic disease. The response to chemotherapy was more favourable in the partial moles. All patients with either partial or complete mole needed hCG assay monitor because of the risk of malignant sequelae.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000097:blood / Q000652:urine; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000175:diagnosis* / Q000188:drug therapy; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D011247:Pregnancy; D012306:Risk; D013577:Syndrome; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000188:drug therapy
D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D005047:Etoposide; D008727:Methotrexate